Helus Pharma (HELP)
Helus Pharma (Cybin Inc.) is a clinical-stage neuropsychiatry biotech focused on psychedelic-derived therapies for depression and anxiety. Its lead asset, CYB003, is in Phase 3 trials for major depressive disorder, with a second program, CYB004, in Phase 2 for generalized anxiety disorder, positioning the company near potential regulatory and commercial inflection points.
7 Surprising Reasons Why Helus Pharma Could Be a Profitable Investment Opportunity for You
Reason #1: Clinical Studies are Already Bringing Astonishingly Positive Results for Helus’s Flagship Drugs
Reason #2: Millions of people around the world are desperate for the relief Helus Pharma’s new drugs in development could offer … and that could, once approved, send sales and profits flying
Reason #3: RFK Jr. is leading the charge to open up the world to new therapies
Reason #4: The FDA’s “Golden Ticket” Is Clearing the Way for Breakthrough New Therapies
Reason #5: Helus Pharma is Building a Robust New Drug Pipeline
Reason #6: Helus Pharma Boasts World Class Leadership and Has Plenty Of Cash
Reason #7: Big Pharma could go on a small-cap buying binge
Helus Pharma News
Access Top Brokerages
